Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
EBITDAEPS (Basic)EPS (Weighted Average and Diluted)Non Operating IncomeOperating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) Income from Continuing Operations (2016 - 2024)

Historic Income from Continuing Operations for Summit Therapeutics (SMMT) over the last 8 years, with Q4 2024 value amounting to -$65.6 million.

  • Summit Therapeutics' Income from Continuing Operations fell 8122.89% to -$65.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$183.2 million, marking a year-over-year decrease of 9497.02%. This contributed to the annual value of -$234.7 million for FY2024, which is 6183.55% up from last year.
  • Latest data reveals that Summit Therapeutics reported Income from Continuing Operations of -$65.6 million as of Q4 2024, which was down 8122.89% from -$60.8 million recorded in Q3 2024.
  • In the past 5 years, Summit Therapeutics' Income from Continuing Operations ranged from a high of -$9.0 million in Q1 2020 and a low of -$65.6 million during Q4 2024
  • For the 4-year period, Summit Therapeutics' Income from Continuing Operations averaged around -$32.8 million, with its median value being -$20.5 million (2023).
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first skyrocketed by 124.15% in 2020, then crashed by 19685.73% in 2024.
  • Quarter analysis of 4 years shows Summit Therapeutics' Income from Continuing Operations stood at -$9.0 million in 2020, then tumbled by 125.55% to -$20.3 million in 2022, then plummeted by 78.38% to -$36.2 million in 2023, then crashed by 81.23% to -$65.6 million in 2024.
  • Its Income from Continuing Operations was -$65.6 million in Q4 2024, compared to -$60.8 million in Q3 2024 and -$36.2 million in Q4 2023.